Ropeginterferon alfa-2b-njft (P1101)

Phase 2Small molecule

Ropeginterferon alfa-2b-njft (P1101) is one of 51 small molecule programs targeting Efficacy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EfficacyActive, not recruiting

EfficacyPhase 2

Active, not recruiting

Competition

Competitive Landscape

139 competitors in Efficacy

#DrugCompanyPhaseTrials

Vabysmo

Roche

Phase 3

2 2

Rayos

RRoxane Laboratories

Phase 3

5 3

Paraplatin

AAvyxa

Phase 3

4 4

Lesinurad

EEsperion Therapeutics, Inc.

Phase 3

2 5

Insulin 320

Novo Nordisk

Phase 3

5 6

Endothelin Receptor Antagonist

RRadboud University Medical Center

Phase 3

1 7

Veracept

SSebela Women's Health Inc.

Phase 3

1 8

Cetaphil

GGalderma R&D

Phase 3

1 9

Aralen

Sanofi

Preclinical

2 10

Primaquine

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Efficacy

NCT05482971

Q3 2027

Phase 3Active, not recruiting

Efficacy

NCT05481151

Clinical

Trials by Indication[1]

Efficacy2 trials

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

Active, not recruiting·PPharmaEssentia·Phase 3·NCT05481151·111 enrolled

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

Active, not recruiting·PPharmaEssentia·Phase 2·NCT05482971·91 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ropeginterferon alfa-2b-njft (P1101). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ropeginterferon alfa-2b-njft (P1101) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ropeginterferon alfa-2b-njft (P1101). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — PharmaEssentia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPharmaEssentia

Ropeginterferon alfa-2b-njft (P1101)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Trials by Indication[1]

Efficacy2 trials

References

Drug Info

Quick Facts

Related News